Avadel Pharmaceuticals Plc (AVDL)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Avadel Pharmaceuticals Plc (AVDL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013571
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:64
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アイルランド
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Avadel Pharmaceuticals Plc (Avadel), formerly Flamel Technologies SA is a specialty pharmaceutical company, which develops and commercializes drugs for allergy, asthma, CNS (narcolepsy), pain, respiratory diseases and diabetes. The company’s product portfolio includes Bloxiverz, Karbinal ER, AchipHex Sprinkle and Vazculep. It develops products based on its proprietary polymer-based technologies; Micropump (oral sustained release microparticles platform), LiquiTime (a Micropump – derivative platform for liquid oral products), Medusa (controlled release of injectables) and for Trigger Lock (a Micropump – derivative platform abuse – resistant opioids). The company has operations in the US (St. Louis, Missouri, and Charlotte) and Dublin, Ireland and markets its products in the US, France and Ireland. Avadel is headquartered in Dublin, Ireland.

Avadel Pharmaceuticals Plc (AVDL) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Avadel Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Avadel Pharmaceuticals Plc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Avadel Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Avadel Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Avadel Pharmaceuticals Plc, Medical Devices Deals, 2011 to YTD 2017 11
Avadel Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
Avadel Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deal Details 14
Partnerships 14
Flamel Technologies Enters Into Product Partnership Agreement With Pharma Company 14
Flamel Technologies Enters Into Co-Development Agreement With Digna Biotech 15
Theralpha Enters Into Co-Development Agreement With Flamel Technologies 17
Merger 18
Flamel Technologies Merges with Avadel Pharma 18
Licensing Agreements 19
Avadel Pharma to Enter into Licensing Agreement with Serenity Pharma for Noctiva 19
Perrigo Enters into Licensing Agreement with Flamel Ireland 21
Tris Pharma And FSC Labs Enter Into Licensing Agreement For Karbinal ER 22
Eagle Pharma Enters Into Licensing Agreement With Flamel Technologies 23
Flamel Technologies Enters Into Licensing Agreement For Micropump Platform 24
Flamel Technologies Enters Into Licensing Agreement For Micropump 25
Equity Offering 26
Flamel to Raise USD13.1 Million in Private Placement of Shares 26
Flamel Technologies Completes Public Offering Of Shares For US$121 Million 27
Debt Offering 29
Flamel Technologies Completes Private Placement Of Notes Due 2017 For US$15 Million 29
Asset Transactions 30
Aytu BioScience Acquires Rights to Primsol from FSC Labs for USD1.8 Million 30
Recipharm Acquires Development and Manufacturing Facility from Flamel for USD13.2 Million 31
Acquisition 33
Flamel Technologies Acquires FSC Holdings 33
Flamel Technologies Acquires Eclat Pharma For US$12 Million 35
Avadel Pharmaceuticals Plc – Key Competitors 37
Avadel Pharmaceuticals Plc – Key Employees 38
Avadel Pharmaceuticals Plc – Locations And Subsidiaries 39
Head Office 39
Other Locations & Subsidiaries 39
Recent Developments 41
Financial Announcements 41
Nov 08, 2017: Avadel Pharmaceuticals Reports Third Quarter 2017 Results 41
Aug 08, 2017: Avadel Pharmaceuticals Reports Second Quarter 2017 Results 43
May 09, 2017: Avadel Pharmaceuticals Reports First Quarter 2017 Results 45
Mar 07, 2017: Avadel Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Results 46
Nov 07, 2016: Flamel Technologies Reports Third Quarter 2016 Results 48
Aug 08, 2016: Flamel Technologies Reports Second Quarter 2016 Results 49
May 09, 2016: Flamel Technologies Reports First Quarter 2016 Results 51
Mar 10, 2016: Flamel Technologies Reports Fourth Quarter and Full Year 2015 Results 52
Corporate Communications 54
Mar 30, 2017: Avadel Pharmaceuticals Announces Planned Reduction of French Workforce 54
Jan 03, 2017: Avadel Pharmaceuticals Appoints Gregory J. Divis Chief Commercial Officer 55
Clinical Trials 56
May 17, 2017: Avadel Pharmaceuticals Supports the Narcolepsy Network’s 5th Annual DREAM BIG Walk 56
Dec 16, 2016: Flamel Technologies Doses First Patient in REST-ON Phase III Trial of FT218 for Excessive Daytime Sleepiness & Cataplexy 57
Oct 06, 2016: Flamel Technologies Reaches Agreement With FDA on Protocol for Phase III Pivotal Trial of FT218 58
Mar 31, 2016: Flamel Technologies Files Special Protocol Assessment for Once Nightly Sodium Oxybate 59
Other Significant Developments 60
Jan 05, 2017: Avadel Pharmaceuticals Provides 2017 Guidance and Business Update 60
Jan 08, 2016: Flamel Technologies Provides Update on Corporate Progress 62
Appendix 64
Methodology 64
About GlobalData 64
Contact Us 64
Disclaimer 64

List of Tables
Avadel Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Avadel Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Avadel Pharmaceuticals Plc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Avadel Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Avadel Pharmaceuticals Plc, Deals By Therapy Area, 2011 to YTD 2017 9
Avadel Pharmaceuticals Plc, Medical Devices Deals, 2011 to YTD 2017 11
Avadel Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
Flamel Technologies Enters Into Product Partnership Agreement With Pharma Company 14
Flamel Technologies Enters Into Co-Development Agreement With Digna Biotech 15
Theralpha Enters Into Co-Development Agreement With Flamel Technologies 17
Flamel Technologies Merges with Avadel Pharma 18
Avadel Pharma to Enter into Licensing Agreement with Serenity Pharma for Noctiva 19
Perrigo Enters into Licensing Agreement with Flamel Ireland 21
Tris Pharma And FSC Labs Enter Into Licensing Agreement For Karbinal ER 22
Eagle Pharma Enters Into Licensing Agreement With Flamel Technologies 23
Flamel Technologies Enters Into Licensing Agreement For Micropump Platform 24
Flamel Technologies Enters Into Licensing Agreement For Micropump 25
Flamel to Raise USD13.1 Million in Private Placement of Shares 26
Flamel Technologies Completes Public Offering Of Shares For US$121 Million 27
Flamel Technologies Completes Private Placement Of Notes Due 2017 For US$15 Million 29
Aytu BioScience Acquires Rights to Primsol from FSC Labs for USD1.8 Million 30
Recipharm Acquires Development and Manufacturing Facility from Flamel for USD13.2 Million 31
Flamel Technologies Acquires FSC Holdings 33
Flamel Technologies Acquires Eclat Pharma For US$12 Million 35
Avadel Pharmaceuticals Plc, Key Competitors 37
Avadel Pharmaceuticals Plc, Key Employees 38
Avadel Pharmaceuticals Plc, Subsidiaries 39

★海外企業調査レポート[Avadel Pharmaceuticals Plc (AVDL)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Kumagai Gumi Co Ltd (1861):企業の財務・戦略的SWOT分析
    Kumagai Gumi Co Ltd (1861) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Mutuelle Generale de l’Education Nationale:企業の戦略的SWOT分析
    Mutuelle Generale de l'Education Nationale - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors an …
  • Fidelity Investments Inc:企業のM&A・事業提携・投資動向
    Fidelity Investments Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Fidelity Investments Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisiti …
  • Industrija nafte dd (INA-R-A):石油・ガス:M&Aディール及び事業提携情報
    Summary Industrija nafte dd (INA) is an integrated energy company, which operates across the energy value chain from exploration and production to refining and marketing to retail. It has interests in offshore and onshore assets in Croatia, Egypt, and Angola. The company manages refineries in Rijeka …
  • Fortis Inc (FTS):石油・ガス:M&Aディール及び事業提携情報
    Summary Fortis Inc (Fortis) is an oil and gas company that provides development of assets and market capitalization programs. The company offers measurement and monitoring of environmental impacts. It also provides capital program and growth plans to meet the energy needs. Fortis support and partici …
  • Quest Diagnostics Incorporated:戦略・SWOT・企業財務分析
    Quest Diagnostics Incorporated - Strategy, SWOT and Corporate Finance Report Summary Quest Diagnostics Incorporated - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • CryoPort Inc (CYRX):製薬・医療:M&Aディール及び事業提携情報
    Summary Cryoport, Inc. (Cryoport) is a provider of cold chain logistics solutions for temperature-sensitive biological materials to the life science industries. It offers liquid nitrogen dry vapor shippers with advanced logistics management platform called Cryoportal, which provides credentials rela …
  • CESC Limited (CESC):企業の財務・戦略的SWOT分析
    CESC Limited (CESC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • IRPC Public Company Limited:企業の戦略・SWOT・財務情報
    IRPC Public Company Limited - Strategy, SWOT and Corporate Finance Report Summary IRPC Public Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Envases Del Plata S.A.
    Envases Del Plata S.A. - Strategy, SWOT and Corporate Finance Report Summary Envases Del Plata S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Custodian & Allied Plc:企業の戦略・SWOT・財務分析
    Custodian & Allied Plc - Strategy, SWOT and Corporate Finance Report Summary Custodian & Allied Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Tokyo Electric Power Company Holdings Incorporated (9501)-石油・ガス分野:企業M&A・提携分析
    Summary Tokyo Electric Power Company Holdings, Incorporated (TEPCO), formerly Tokyo Electric Power Company, Incorporated, is an integrated energy company. The company generates, transmits, distributes and sells electricity through its subsidiaries. It generates power from various sources such as the …
  • Laboratoires Pierre Fabre SA:企業の戦略的SWOT分析
    Laboratoires Pierre Fabre SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • HTC Corporation:企業のM&A・事業提携・投資動向
    HTC Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's HTC Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestm …
  • China Chemical & Pharmaceutical Co Ltd (1701):企業の財務・戦略的SWOT分析
    China Chemical & Pharmaceutical Co Ltd (1701) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key stre …
  • NorgesGruppen ASA:企業の戦略的SWOT分析
    NorgesGruppen ASA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • EQUATE Petrochemical Co:企業の戦略的SWOT分析
    EQUATE Petrochemical Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • China Suntien Green Energy Co Ltd (956):企業の財務・戦略的SWOT分析
    China Suntien Green Energy Co Ltd (956) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Broncus Medical Inc:医療機器:M&Aディール及び事業提携情報
    Summary Broncus Medical Inc (Broncus), formerly Broncus Technologies Inc is a medical device company that develops navigation, diagnostic and therapeutic technologies for the treatment of patients with lung disease. The company offers Archimedes system, a total lung access platform used for virtual …
  • Heat Biologics Inc (HTBX):企業の財務・戦略的SWOT分析
    Heat Biologics Inc (HTBX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆